Favipiravir (T-705)

製品コードS7975 バッチS797504

印刷

化学情報

Chemical Structure Synonyms N/A Storage
(From the date of receipt)		 3 years -20°C powder
1 years -80°C in solvent
化学式

C5H4FN3O2
分子量 157.1 CAS No. 259793-96-9
Solubility (25°C)* 体外 DMSO 31 mg/mL (197.32 mM)
Ethanol (warmed with 50ºC water bath) 20 mg/mL (127.3 mM)
Water (warmed with 50ºC water bath) 12 mg/mL (76.38 mM)
体内 （毎回新しく調製した物を用意してください）
Homogeneous suspension
CMC-NA
≥5mg/ml Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

溶剤液（一定の濃度）を調合する

生物活性

製品説明 Favipiravir (T-705) is a potent and selective RNA-dependent RNA polymerase inhibitor, used to treat influenza virus infections.
in vitro Favipiravir (T-705) shows anti-influenza virus activities with IC50 ranged from 0.013 to 0.48 μg/ml for the influenza A viruses, from 0.039 to 0.089 μg/ml for the influenza B viruses, and from 0.030 to 0.057 μg/ml for the influenza C viruses. In mammalian cell lines (MDCK cells, Vero cells, HEL cells, A549 cells, HeLa cells, and HEp-2 cells), it shows no cytotoxicity at concentrations up to 1,000 μg/ml. [1] In MDCK cells inoculated with seasonal influenza A (H1N1) viruses, this compound induces lethal mutagenesis. [2]
in vivo Favipiravir (T-705) protects influenza virus-infected mice from death (200 mg/kg/day, p.o.) and efficiently blocks viral production in mice experimentally infected with Ebola virus, reaching an antiviral effectiveness of 95% and 99.6% at 2 and 6 days after initiation of treatment, respectively. [1][3]

プロトコル(参考用のみ)

細胞アッセイ 細胞株 MDCK cells, Vero cells, HEL cells, A549 cells, HeLa cells, and HEp-2 cells
濃度 1000 μg/mL
反応時間 3 days
実験の流れ The cytotoxicity of Favipiravir (T-705) is evaluated by an assay with XTT. XTT is converted to aqueous formazan by an enzyme in MDCK cells, Vero cells, HEL cells, A549 cells, HeLa cells, and HEp-2 cells. The compound is diluted to the appropriate concentrations (volume, 100 μl) with test medium (EMEM containing 10% FCS) in 96-well culture plates in which each well contains a concentration of 2 × 103 cells/100 μL. The test plates are incubated for 3 days at 37°C in 100% humidity and 5% CO2. After 3 days, 50 μl of the XTT reagent (1 mg/ml in FCS-free EMEM containing 5 mM phenazine methosulfate) is added, and the reaction product is assayed by measurement of the absorbance at 450 nm with a microplate reader. Cytotoxicity is expressed as the 50% cell-inhibitory concentration (CC50).
動物実験 動物モデル Mice infected with influenza virus A/PR/8/34
投薬量 200 mg/kg/day
投与方法 p.o.

参考

  • https://pubmed.ncbi.nlm.nih.gov/11897578/
  • https://pubmed.ncbi.nlm.nih.gov/23325689/
  • https://pubmed.ncbi.nlm.nih.gov/26343011/

カスタマーフィードバック

Data from [Data independently produced by , , Cell Physiol Biochem, 2018, 49(1):381-394]

Data from [Data independently produced by , , Antiviral Res, 2017, 143:237-245]

Selleckの高級品が、幾つかの出版された研究調査結果（以下を含む）で使われた：

Differential tropisms of old and new world hantaviruses influence virulence and developing host-directed antiviral candidates [ PLoS Pathog, 2025, 21(8):e1013401] PubMed: 40857262
Dysregulated glycerophospholipid metabolism in amygdala may mediate favipiravir-induced anxiety-like behaviors in mice [ Front Pharmacol, 2025, 16:1491150] PubMed: 40103591
Favipiravir as a potent inhibitor of Newcastle disease virus: in ovo efficacy, dose-dependent toxicity, and molecular insights into RNA polymerase inhibition [ Vet World, 2025, 18(9):2785-2797] PubMed: 41113231
Identification of dihydroorotate dehydrogenase inhibitor, vidofludimus, as a potent and novel inhibitor for influenza virus [ J Med Virol, 2024, 96(1):e29372] PubMed: 38235544
High-dose modified-release formulation of a poorly soluble drug via twin-screw melt coating and granulation [ Int J Pharm, 2024, 670:125090] PubMed: 39681221
ProcCluster® and procaine hydrochloride inhibit the growth of Aspergillus species and exert antimicrobial properties during coinfection with influenza A viruses and A. fumigatus in vitro [ Front Cell Infect Microbiol, 2024, 14:1445428] PubMed: 39473925
ヒト iPS 細胞由来心筋細胞を用いた慢性収縮毒性評価法の開発 [ Okayama University, 2023 , 10.18926/65391] PubMed: none
Ebola virus VP35 hijacks the PKA-CREB1 pathway for replication and pathogenesis by AKIP1 association [ Nat Commun, 2022, 13(1):2256] PubMed: 35474062
TRIM25 inhibits influenza A virus infection, destabilizes viral mRNA, but is redundant for activating the RIG-I pathway [ Nucleic Acids Res, 2022, gkac512] PubMed: 35736141
In vitro and in vivo efficacy of a novel nucleoside analog H44 against Crimean-Congo hemorrhagic fever virus [ Antiviral Res, 2022, 199:105273] PubMed: 35257725

長期の保管のために-20°Cの下で製品を保ってください。

人間や獣医の診断であるか治療的な使用のためにでない。

各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。